ICML 2015 Poster Session: Healthcare utilisation in the AETHERA trial: phase 3 study of brentuximab vedotin in patients at increased risk of residual Hodgkin lymphoma post-ASCT
Vijayveer Bonthapally et al, Cambridge, MA, USA / by Maria Dalby. AETHERA is a randomised, placebo-controlled phase III study to evaluate whether consolidation treatment with brentuximab vedotin can… read more.